Human medicines Modular Manufacture and Point of Care 2025

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued new guidance regarding the Human Medicines (Amendment) Modular Manufacture and Point of Care regulations 2025. This regulatory framework is designed to govern medicines manufactured at or near the point of patient care, such as in clinical settings or via mobile modular units. Unlike traditional manufacturing, point-of-care (POC) models present unique challenges for quality control and oversight. The regulations aim to bridge the gap between innovation in personalized medicine and existing safety standards. While this document is a general guidance rather than an inspection report for a specific company, it highlights that the primary issues addressed are the lack of formal oversight for decentralized manufacturing and the need for a unified pharmaceutical quality system. The framework introduces the 'Control Site' model, requiring a central authorized facility to oversee all POC manufacturing nodes. Required actions for stakeholders include registering all point-of-care locations under a single Control Site license and ensuring that each site adheres to the same quality standards as centralized facilities. Organizations must prepare for these changes before the 2025 implementation by establishing robust governance structures and seeking necessary MHRA authorizations. This approach ensures that medical products manufactured in modular units maintain the highest levels of safety and efficacy for UK patients.